intermediate12 min read

How to Read a 10-K for Biotech Companies

Reviewed by Blane Jackson, DDS, MBA. Educational guide only. See the editorial policy and disclosures.

If you're investing in biotech, the 10-K is your best friend—but it's also a dense, jargon-filled document that can intimidate even seasoned investors. For clinical-stage biotechs, the 10-K reveals the company's financial health, its pipeline progress, and the risks that could sink your investment. In this guide, we'll cut through the legalese and show you exactly what to look for: cash runway, R&D spending, going-concern warnings, and the red flags that many investors miss. By the end, you'll be able to quickly assess a biotech's 10-K and make more informed decisions. Let's dive in.

1. Start with the Business Overview: What Are They Actually Doing?

The first section of a 10-K (Item 1) describes the company's business. For a biotech, this is where you'll find a plain-English summary of their technology, pipeline, and target diseases. Don't skip this—it sets the stage for everything else. Look for: (1) The company's lead programs and what phase they're in. (2) The specific disease areas they're targeting. (3) Any platform technology that could produce multiple drugs. For example, Moderna's 10-K highlights its mRNA platform, which allows it to develop vaccines and therapeutics rapidly. If a company has a broad platform, it may be more resilient if one drug fails. Conversely, if they're a single-asset company, the risk is much higher. Also, check the 'Human Capital' section—biotech is all about people. Are they hiring experienced executives? Any recent departures? A revolving door in the C-suite is a red flag.

Key takeaway

The business overview tells you what the company does and how diversified its pipeline is. A platform approach can reduce risk, while a single-asset company is a binary bet.

Example

Moderna's 10-K emphasizes its mRNA platform, which allowed it to pivot quickly to COVID-19 vaccines. This platform narrative is a key reason investors value the company beyond its initial product.

2. Cash Runway: How Long Before They Run Out of Money?

Cash is king in biotech. A clinical-stage company typically has no revenue, so it burns through cash to fund R&D. The 10-K's financial statements (Item 8) will show you the cash position and the cash burn rate. To calculate the runway, divide the cash on hand by the quarterly cash burn (or annual burn). For example, if a company has $100 million in cash and burns $25 million per quarter, it has about 4 quarters of runway. But don't stop there—read the Management Discussion & Analysis (MD&A, Item 7) for management's own assessment. They often state how long they expect their cash to last, assuming no additional financing. This is crucial because if the runway is less than 12 months, the company will likely need to raise capital soon, which could dilute your shares. Look for the phrase 'going concern'—if the auditors have doubts about the company's ability to continue, they'll flag it. That's a major red flag.

Key takeaway

Always calculate the cash runway and compare it to the company's stated milestones. If they need to raise money within the next year, expect dilution.

Example

In 2023, many small biotechs had less than 12 months of cash runway due to a tough financing environment. For instance, a company like Sio Gene Therapies had to wind down operations after failing to secure funding, illustrating the importance of monitoring runway.

Ready to start? Open a Webull account and trade biotech stocks commission-freevia Webull · Affiliate

3. R&D Spending: Are They Investing Wisely?

Research and development (R&D) is the lifeblood of a biotech. In the income statement, you'll see R&D expenses. But the raw number isn't enough—you need to look at how it's being spent. Read the MD&A for a breakdown: how much is going to each clinical program? Are they advancing multiple candidates or just one? A company that spreads its R&D too thin across many programs might not have enough resources to bring any to market. Also, look at the ratio of R&D to general and administrative (G&A) expenses. If G&A is disproportionately high, it might indicate inefficiency or excessive executive pay. For example, a company with $50 million in R&D and $30 million in G&A might be spending too much on overhead. Compare R&D spending to the stage of the pipeline: a Phase 3 trial costs much more than a Phase 1, so a company with a late-stage pipeline should have higher R&D.

Key takeaway

R&D spending should be aligned with the pipeline's stage and strategy. Watch for companies that are underfunding promising programs or overpaying executives.

Example

In 2020, Bristol Myers Squibb's 10-K showed R&D expenses of over $11 billion, reflecting its heavy investment in late-stage oncology drugs. In contrast, a micro-cap biotech might spend only $10 million on R&D, which is typical for early-stage research.

4. The Risk Factors: Where the Landmines Are

Item 1A, 'Risk Factors,' is often the longest part of the 10-K, and for good reason. Biotech companies are required to disclose every material risk they face. This is where you'll find the real red flags. Look for: (1) Risks related to clinical trials—will they get the results they expect? (2) Regulatory risks—will the FDA approve their drug? (3) Competition—are there better drugs in development? (4) Intellectual property—do they have strong patents? (5) Financing risks—will they need to raise capital? But beware: companies often bury the most serious risks in boilerplate language. For example, a company might say, 'We may need additional financing to continue our operations,' which is a euphemism for 'we're running out of cash.' Also, look for any risk factors that are specific to the company, not generic industry risks. If a risk factor mentions a specific trial failure or regulatory setback, that's a huge red flag.

Key takeaway

The risk factors section is a treasure trove of red flags. Focus on company-specific risks, not generic ones, and read between the lines for financial distress.

Example

In 2022, a biotech like Athenex had a risk factor stating that it might not be able to continue as a going concern, and indeed, it later filed for bankruptcy. The warning was there for investors who read carefully.

5. Financial Statements: The Numbers Behind the Story

The financial statements (Item 8) include the balance sheet, income statement, and cash flow statement. For a clinical-stage biotech, the balance sheet shows cash, debt, and shareholder equity. The income statement will show R&D and G&A expenses, but no revenue (or minimal revenue from collaborations). The cash flow statement is critical: it shows operating cash flow (cash used in operations), investing cash flow (e.g., purchases of equipment), and financing cash flow (e.g., proceeds from stock offerings). Look at the operating cash flow—it should be negative, reflecting cash burn. But also look at financing cash flow: if the company is raising money through stock offerings, you'll see it here. This tells you how much dilution has occurred. Also, check the notes to the financial statements for details on stock-based compensation, which can be a significant expense. A company that issues a lot of stock options may be diluting shareholders more than the income statement suggests.

Key takeaway

The cash flow statement reveals the true cash burn and financing activities. Watch for heavy stock-based compensation, which is a hidden cost to shareholders.

Example

A company like CRISPR Therapeutics, in its 2023 10-K, showed a net loss of over $200 million, but its cash flow statement revealed that most of its cash burn was from R&D, not executive compensation. This is a good sign.

6. Red Flags Investors Miss: Going Concern, Debt, and Insider Selling

Beyond the obvious, there are subtle red flags in a 10-K. First, the 'going concern' note in the auditor's report. If the auditor has substantial doubt about the company's ability to continue for the next year, they'll issue a going concern opinion. This is a huge warning sign. Second, look at the debt structure. If a company has debt, especially convertible debt, it could lead to dilution or bankruptcy if not managed well. Third, check the 'Insider Transactions' section (though not always in the 10-K, it's in the proxy statement). If insiders are selling large amounts of stock, it might indicate they lack confidence. Finally, look at the 'Legal Proceedings' section—pending lawsuits can be a drain on resources. For example, a patent infringement lawsuit could threaten the company's entire business.

Key takeaway

Going concern opinions, high debt, insider selling, and legal battles are major red flags that often go unnoticed by retail investors.

Example

In 2021, a biotech like Celsion Corporation had a going concern opinion in its 10-K, and its stock subsequently plummeted. Investors who noticed this early could have avoided losses.

Key terms

10-K

An annual report filed with the SEC that provides a comprehensive summary of a company's financial performance and business operations. It includes audited financial statements and detailed disclosures.

Cash Runway

The amount of time a company can continue to operate before it runs out of cash, calculated by dividing current cash by monthly or quarterly burn rate.

Going Concern

An accounting term indicating whether a company has the resources to continue operating for at least the next 12 months. If not, auditors issue a 'going concern' warning.

R&D Expenses

Research and development costs, including salaries, lab supplies, clinical trial costs, and regulatory expenses. For biotechs, this is the largest expense category.

MD&A (Management Discussion & Analysis)

A section of the 10-K where management explains the financial results, business conditions, and future outlook. It provides context to the raw numbers.

Dilution

The reduction in existing shareholders' ownership percentage due to the issuance of new shares, often through secondary offerings or stock options.

Balance Sheet

A financial statement that shows a company's assets, liabilities, and shareholders' equity at a specific point in time.

Income Statement

A financial statement that shows revenues, expenses, and net income or loss over a period of time.

Cash Flow Statement

A financial statement that shows the inflows and outflows of cash from operating, investing, and financing activities.

Stock-Based Compensation

A form of payment to employees using stock options or restricted stock. It is an expense that can dilute shareholders but doesn't require cash outlay.

Next steps

Download the latest 10-K from the SEC EDGAR database (or the company's IR page) for any biotech you're considering.

Calculate the cash runway: divide cash and equivalents by the quarterly cash burn (from the cash flow statement). If it's less than 12 months, note the risk.

Read the Risk Factors section and highlight any that are specific to the company's pipeline, financing, or intellectual property.

Compare R&D spending to the stage of the pipeline. If a Phase 3 company is spending less than $50 million annually, question whether they can complete the trial.

Check the auditor's opinion for a 'going concern' note. If present, treat it as a major red flag.

Put this guide to work

Use these free ClinicalInvestor tools to apply what you just learned.

2026 PDUFA Calendar →

Every FDA decision in 2026 with AI investor analysis.

Biotech Catalyst Calendar →

PDUFA dates, Phase 3 readouts, AdComs, and conferences. Free.

Trial Translator →

Paste any ClinicalTrials.gov ID and get a plain-English AI breakdown.

Biotech Screener →

Filter published biotech profiles by area, phase, market cap, and runway.

Company Profiles →

Pipelines, bull and bear cases, and next expected data for every covered biotech.

Keep learning

Understanding Cash Runway for Biotech Stocks →Understanding Biotech Financials →Biotech Dilution and Secondary Offerings Explained →Biotech Risk Management →